Suhendan Ekmekcioglu, Ph.D.

Peer-Reviewed Articles

1. Kim SH, Roszik J, Cho SN, Ogata D, Milton DR, Peng W, Menter DG, Ekmekcioglu S, and Grimm EA. The COX2 effector microsomal PGE2 synthase-1 is a regulator of immunosuppression in cutaneous melanoma. Clinical Cancer Research 25(5):1650-1663, 2019. PMID: 30538110.
2. Dal Yontem F, Kim SH, Ding Z, Grimm E, Ekmekcioglu S, Akcakaya H. Mitochondrial dynamic alterations regulate melanoma cell progression. J Cell Biochem 120:2098-2108, 2019. e-Pub 2018. PMID: 30256441.
3. Kim SH, Roszik J, Grimm EA, Ekmekcioglu S. Impact of L-Arginine Metabolism on Immune Response and Anti-Cancer Immunotherapy. Front Oncol 8:67, 2018. e-Pub 2018. PMID: 29616189.
4. Gianni M, Qin Y, Wenes G, Bandstra B, Conley AP, Subbiah V, Leibowitz-Amit R, Ekmekcioglu S, Grimm EA, Roszik J.. High-Throughput Architecture for Discovering Combination Cancer Therapeutics. JCO Clinical Cancer Informatics, 2018. e-Pub 2018.
5. Roszik J, Tanese K, Ekmekcioglu S. Editorial: Targeting Metabolism in Cancer Immunotherapy. Front Immunol 9:2029, 2018. e-Pub 2018. PMID: 30254633.
6. Ekmekcioglu S, Grimm EA, Roszik J. Targeting iNOS to increase efficacy of immunotherapies. Hum Vaccin Immunother 13(5):1105-1108, 2017. e-Pub 2017. PMID: 28121247.
7. Tanese K, Funakoshi T, Yasuda F, Ohi Y, Fukuyama M, Arakawa H, Ekmekcioglu S, Saito M. Case of squamous cell carcinoma showing delayed metastasis and histologically exhibiting alterations of the surrounding immune cell populations along with the tumor invasion: Expression of monocyte chemotactic protein-1 in deeply invaded tumor cells and interleukin-6 in surrounding histiocytes. J Dermatol 44(3):346-348, 2017. e-Pub 2016. PMID: 27667796.
8. Maturu P, Jones D, Ruteshouser EC, Hu Q, Reynolds JM, Hicks J, Putluri N, Ekmekcioglu S, Grimm EA, Dong C, Overwijk WW. Role of Cyclooxygenase-2 Pathway in Creating an Immunosuppressive Micro Environment and in Initiation and Progression of Wilms Tumor. Neoplasia 19(3):237-249, 2017. PMID: 28254151.
9. Qin Y, Ekmekcioglu S, Forget MA, Szekvolgyi L, Hwu P, Grimm EA, Jazaeri AA, Roszik J. Cervical Cancer Neoantigen Landscape and Immune Activity Is Associated with Human Papillomavirus Master Regulators. Front Immunol 8:689, 2017. e-Pub 2017. PMID: 28670312.
10. Qin Y, Roszik J, Chattopadhyay C, Hashimoto Y, Liu C, Cooper ZA, Wargo JA, Hwu P, Ekmekcioglu S, Grimm EA. Hypoxia-driven mechanism of vemurafenib resistance in melanoma. Mol Cancer Ther 15(10):2442-2454, 2016. e-Pub 2016. PMID: 27458138.
11. Bailey P, Chang DK, Forget MA, Lucas FA, Alvarez HA, Haymaker C, Chattopadhyay C, Kim SH, Ekmekcioglu S, Grimm EA, Biankin AV, Hwu P, Maitra A, Roszik J. Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma. Sci Rep 6(35848):35848, 2016. e-Pub 2016. PMID: 27762323.
12. Ekmekcioglu S, Davies MA, Tanese K, Roszik J, Shin-Sim M, Bassett RL, Milton DR, Woodman SE, Prieto VG, Gershenwald JE, Morton DL, Hoon DS, Grimm EA. Inflammatory Marker Testing Identifies CD74 Expression in Melanoma Tumor Cells, and its Expression Associates with Favorable Survival for Stage III Melanoma. Clin Cancer Res 22(12):3016-24, 2016. e-Pub 2016. PMID: 26783288.
13. Kim SH, Hashimoto Y, Cho SN, Roszik J, Milton DR, Dal F, Kim SF, Menter DG, Yang P, Ekmekcioglu S, Grimm EA. Microsomal PGE2 synthase-1 promotes melanoma progression via regulating cell survival. Pigment Cell Melanoma Res 29(3):297-308, 2016. e-Pub 2016. PMID: 26801201.
14. Rai K, Akdemir KC, Kwong LN, Fiziev P, Wu CJ, Keung EZ, Sharma S, Samant NS, Williams M, Axelrad JB, Shah A, Yang D, Grimm EA, Barton MC, Milton DR, Heffernan TP, Horner JW, Ekmekcioglu S, Lazar AJ, Ernst J, Chin L. Dual Roles of RNF2 in Melanoma Progression. Cancer Discov 5(12):1314-27, 2015. e-Pub 2015. PMID: 26450788.
15. Tanese K, Hashimoto Y, Berkova Z, Wang Y, Samaniego F, Lee JE, Ekmekcioglu S, Grimm EA. Cell Surface CD74-MIF Interactions Drive Melanoma Survival in Response to Interferon-γ. J Invest Dermatol 135(11):2775-84, 2015. e-Pub 2015. PMID: 26039541.
16. Qin Y, Milton DR, Oba J, Ding Z, Lizée G, Ekmekcioglu S, Grimm EA. Inflammatory IL-1β-driven JNK activation in stage III melanoma. Pigment Cell Melanoma Res 28(2):236-9, 2015. e-Pub 2015. PMID: 25546243.
17. Maturu P, Overwijk WW, Hicks J, Ekmekcioglu S, Grimm EA, Huff V. Characterization of the inflammatory microenvironment and identification of potential therapeutic targets in wilms tumors. Transl Oncol 7(4):484-92, 2014. e-Pub 2014. PMID: 24969538.
18. Hong DS, Garrido-Laguna I, Ekmekcioglu S, Falchook GS, Naing A, Wheler JJ, Fu S, Moulder SL, Piha-Paul S, Tsimberidou AM, Wen Y, Culotta KS, Anderes K, Davis DW, Liu W, George GC, Camacho LH, Percy Ivy S, Kurzrock R. Dual inhibition of the vascular endothelial growth factor pathway: a phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors. Cancer 120(14):2164-73, 2014. e-Pub 2014. PMID: 24752867.
19. Wang Y, Hu S, Gabisi AM, Er JA, Pope A, Burstein G, Schardon CL, Cardounel AJ, Ekmekcioglu S, Fast W. Developing an irreversible inhibitor of human DDAH-1, an enzyme upregulated in melanoma. ChemMedChem 9(4):792-7, 2014. e-Pub 2014. PMID: 24574257.
20. Lopez-Rivera E, Jayaraman P, Parikh F, Davies MA, Ekmekcioglu S, Izadmehr S, Milton DR, Chipuk JE, Grimm EA, Estrada Y, Aguirre-Ghiso J, Sikora AG. Inducible nitric oxide synthase (iNOS) drives mTOR pathway activation and proliferation of human melanoma by reversible nitrosylation of TSC2. Cancer Res 74(4):1067-78, 2014. e-Pub 2014. PMID: 24398473.
21. Grimm EA, Sikora AG, Ekmekcioglu S. Molecular Pathways: Inflammation-associated nitric-oxide production as a cancer-supporting redox mechanism and a potential therapeutic target. Clin Cancer Res 19(20):5557-5563, 2013. e-Pub 2013. PMID: 23868870.
22. Zhou H, Ekmekcioglu S, Marks JW, Mohamedali KA, Asrani K, Phillips KK, Brown SA, Cheng E, Weiss MB, Hittelman WN, Tran NL, Yagita H, Winkles JA, Rosenblum MG. The TWEAK Receptor Fn14 Is a Therapeutic Target in Melanoma: Immunotoxins Targeting Fn14 Receptor for Malignant Melanoma Treatment. J Invest Dermatol 133(4):1052-62, 2013. e-Pub 2012. PMID: 23190886.
23. Qin Y, Deng W, Ekmekcioglu S, Grimm EA. Identification of unique sensitizing targets for anti-inflammatory CDDO-Me in metastatic melanoma by a large-scale synthetic lethal RNAi screening. Pigment Cell Melanoma Res 26(1):97-112, 2013. e-Pub 2012. PMID: 23020131.
24. Yoon JK, Frankel AE, Feun LG, Ekmekcioglu S, Kim KB. Arginine deprivation therapy for malignant melanoma. Clin Pharmacol 5:11-9, 2013. e-Pub 2012. PMID: 23293541.
25. Khalili JS, Liu S, Rodríguez-Cruz TG, Whittington M, Wardell S, Liu C, Zhang M, Cooper ZA, Frederick DT, Li Y, Zhang M, Joseph RW, Bernatchez C, Ekmekcioglu S, Grimm E, Radvanyi LG, Davis RE, Davies MA, Wargo JA, Hwu P, Lizée G. Oncogenic BRAF(V600E) Promotes Stromal Cell-Mediated Immunosuppression Via Induction of Interleukin-1 in Melanoma. Clin Cancer Res 18(19):5329-40, 2012. e-Pub 2012. PMID: 22850568.
26. Tanese K, Grimm EA, Ekmekcioglu S. The role of melanoma tumor-derived nitric oxide in the tumor inflammatory microenvironment: Its impact on the chemokine expression profile, including suppression of CXCL10. Int J Cancer 131(4):891-901, 2012. e-Pub 2011. PMID: 21953496.
27. Chattopadhyay C, Ellerhorst JA, Ekmekcioglu S, Greene VR, Davies MA, Grimm EA. Association of Activated c-Met with NRAS-Mutated Human Melanomas: A Possible Avenue for Targeting. Int J Cancer 131(2):56-65, 2012. e-Pub 2012. PMID: 22020736.
28. Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K, Agholme L, Agnello M, Agostinis P, Aguirre-Ghiso JA, Ahn HJ, Ait-Mohamed O, Ait-Si-Ali S, Akematsu T, Akira S, Al-Younes HM, Al-Zeer MA, Albert ML, Albin RL, Alegre-Abarrategui J, Aleo MF, Alirezaei M, Almasan A, Almonte-Becerril M, Amano A, Amaravadi R, Amarnath S, Amer AO, Andrieu-Abadie N, Anantharam V, Ann DK, Anoopkumar-Dukie S, Aoki H, Apostolova N, Auberger P, Baba M, Backues SK, Baehrecke EH, Bahr BA, Bai XY, Bailly Y, Baiocchi R, Baldini G, Balduini W, Ballabio A, Bamber BA, Bampton ET, Bánhegyi G, Bartholomew CR, Bassham DC, Bast RC, Batoko H, Bay BH, Beau I, Béchet DM, Begley TJ, Behl C, Behrends C, Bekri S, Bellaire B, Bendall LJ, Benetti L, Berliocchi L, Bernardi H, Bernassola F, Besteiro S, Bhatia-Kissova I, Bi X, Biard-Piechaczyk M, Blum JS, Boise LH, Bonaldo P, Boone DL, Bornhauser BC, Bortoluci KR, Bossis I, Bost F, Bourquin JP, Boya P, Boyer-Guittaut M, Bozhkov PV, Brady NR, Brancolini C, Brech A, Brenman JE, Brennand A, Bresnick EH, Brest P, Bridges D, Bristol ML, Brookes PS, Brown EJ, Brumell JH, Brunetti-Pierri N, Brunk UT, Bulman DE, Bultman SJ, Bultynck G, Burbulla LF, Bursch W, Butchar JP, Buzgariu W, Bydlowski SP, Cadwell K, Cahová M, Cai D, Cai J, Cai Q, Calabretta B, Calvo-Garrido J, Camougrand N, Campanella M, Campos-Salinas J, Candi E, Cao L, Caplan AB, Carding SR, Cardoso SM, Carew JS, Carlin CR, Carmignac V, Carneiro LA, Carra S, Caruso RA, Casari G, Casas C, Castino R, Cebollero E, Cecconi F, Celli J, Chaachouay H, Chae HJ, Chai CY, Chan DC, Chan EY, Chang RC, Che CM, Chen CC, Chen GC, Chen GQ, Chen M, Chen Q, Chen SS, Chen W, Chen X, Chen X, Chen X, Chen YG, Chen Y, Chen Y, Chen YJ, Chen Z, Cheng A, Cheng CH, Cheng Y, Cheong H, Cheong JH, Cherry S, Chess-Williams R, Cheung ZH, Chevet E, Chiang HL, Chiarelli R, Chiba T, Chin LS, Chiou SH, Chisari FV, Cho CH, Cho DH, Choi AM, Choi D, Choi KS, Choi ME, Chouaib S, Choubey D, Choubey V, Chu CT, Chuang TH, Chueh. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 8(4):445-544, 2012. PMID: 22966490.
29. Qin Y, Ekmekcioglu S, Liu P, Duncan LM, Lizée G, Poindexter N, Grimm EA. Constitutive Aberrant Endogenous Interleukin-1 Facilitates Inflammation and Growth in Human Melanoma. Mol Cancer Res 9(11):1537-50, 2011. e-Pub 2011. PMID: 21954434.
30. Ekmekcioglu S, Chattopadhyay C, Akar U, Gabisi A, Newman RA, Grimm EA. Zyflamend Mediates Therapeutic Induction of Autophagy to Apoptosis in Melanoma Cells. Nutr Cancer 63(6):940-9, 2011. e-Pub 2011. PMID: 21745040.
31. Deng WG, Kwon J, Ekmekcioglu S, Poindexter NJ, Grimm EA. IL-24 gene transfer sensitizes melanoma cells to erlotinib through modulation of the Apaf-1 and Akt signaling pathways. Melanoma Res 21(1):44-56, 2011. e-Pub 2010. PMID: 20216471.
32. Ellerhorst JA, Greene VR, Ekmekcioglu S, Warneke CL, Johnson MM, Cooke CP, Wang LE, Prieto VG, Gershenwald JE, Wei Q, Grimm EA. Clinical Correlates of NRAS and BRAF Mutations in Primary Human Melanoma. Clin Cancer Res 17(2):229-35, 2011. e-Pub 2010. PMID: 20975100.
33. Huerta-Yepez S, Ekmekcioglu S, Rivera-Pazos CM, Antonio-Andres G, Vega MI, Baay-Guzman G, Grimm EA. Braf Mutations Are Associated With High Levels of Phosphorylated RKIP in Melanoma Cell Lines: Potential Prognostic Significance. Forum on Immunopathological Diseases and Therapeutics 2(2):189-194, 2011.
34. Sikora AG, Gelbard A, Davies MA, Sano D, Ekmekcioglu S, Kwon J, Hailemichael Y, Jayaraman P, Myers JN, Grimm EA, Overwijk WW. Targeted inhibition of inducible nitric oxide synthase inhibits growth of human melanoma in vivo and synergizes with chemotherapy. Clin Cancer Res 16(6):1834-44, 2010. e-Pub 2010. PMID: 20215556.
35. Zheng M, Bocangel D, Ramesh R, Ekmekcioglu S, Poindexter N, Grimm EA, Chada S. Interleukin-24 overcomes temozolomide resistance and enhances cell death by down-regulation of O6-methylguanine-DNA methyltransferase in human melanoma cells. Mol Cancer Ther 7(12):3842-51, 2008. e-Pub 2008. PMID: 19056673.
36. Grimm EA, Ellerhorst J, Tang CH, Ekmekcioglu S. Constitutive Intracellular Production of iNOS and NO in Human Melanoma: Possible Role in Regulation of Growth and Resistance to Apoptosis. Nitric Oxide 19(2):133-37, 2008. e-Pub 2008. PMID: 18472017.
37. Hwang CS, Prieto VG, Diwan AH, Lizee G, Ellerhorst JA, Ekmekcioglu S, Liu P, Eton O, Kinney SA, Grimm EA, Hwu P, Kim KB. Changes in pERK1/2 and p-AKT Expression in Melanoma Lesions after Imatinib Treatment. Melanoma Res 18(4):241-45, 2008. e-Pub 2008. PMID: 18626307.
38. Ekmekcioglu S, Mumm JB, Udtha M, Chada S, Grimm EA. Killing of human melanoma cells induced by activation of class I interferon-regulated signaling pathways via MDA-7/IL-24. Cytokine 43(1):34-44, 2008. e-Pub 2008. PMID: 18511292.
39. Zheng M, Bocangel D, Doneske B, Mhashilkar A, Ramesh R, Hunt KK, Ekmekcioglu S, Sutton RB, Poindexter N, Grimm EA, Chada S. Human interleukin 24 (MDA-7/IL-24) protein kills breast cancer cells via the IL-20 receptor and is antagonized by IL-10. Cancer Immunol Immunother 56(2):205-15, 2007. e-Pub 2006. PMID: 16710719.
40. Mumm JB, Ekmekcioglu S, Poindexter NJ, Chada S, Grimm EA. Soluble human MDA-7/IL-24: characterization of the molecular form(s) inhibiting tumor growth and stimulating monocytes. J Interferon Cytokine Res 26(12):877-86, 2006. PMID: 17238830.
41. Ekmekcioglu S, Ellerhorst JA, Prieto VG, Johnson MM, Broemeling LD, Grimm EA. Tumor iNOS predicts poor survival for stage III melanoma patients. Int J Cancer 119(4):861-6, 2006. PMID: 16557582.
42. Fok JY, Ekmekcioglu S, Mehta K. Implications of tissue transglutaminase expression in malignant melanoma. Mol Cancer Ther 5:1493-503, 2006. PMID: 16818508.
43. Ellerhorst JA, Ekmekcioglu S, Johnson MK, Cooke CP, Johnson MM, Grimm EA. Regulation of iNOS by the p44/42 mitogen-activated protein kinase pathway in human melanoma. Oncogene 25(28):3956-62, 2006. e-Pub 2006. PMID: 16474847.
44. Tong AW, Nemunaitis J, Su D, Zhang Y, Cunningham C, Senzer N, Netto G, Rich D, Mhashilkar A, Parker K, Coffee K, Ramesh R, Ekmekcioglu S, Grimm EA, van Wart Hood J, Merritt J, Chada S. Intratumoral injection of INGN 241, a nonreplicating adenovector expressing the melanoma-differentiation associated gene-7 (mda-7/IL24): biologic outcome in advanced cancer patients. Mol Ther 11(1):160-72, 2005. PMID: 15585417.
45. Chada S, Mhashilkar AM, Ramesh R, Mumm JB, Sutton RB, Bocangel D, Zheng M, Grimm EA, Ekmekcioglu S. Bystander activity of Ad-mda7: human MDA-7 protein kills melanoma cells via an IL-20 receptor-dependent but STAT3-independent mechanism. Mol Ther 10(6):1085-95, 2004. PMID: 15564140.
46. Zheng M, Ekmekcioglu S, Walch ET, Tang CH, Grimm EA. Inhibition of nuclear factor-kappaB and nitric oxide by curcumin induces G2/M cell cycle arrest and apoptosis in human melanoma cells. Melanoma Res 14(3):165-71, 2004. PMID: 15179184.
47. Ekmekcioglu S, Ellerhorst JA, Mumm JB, Zheng M, Broemeling L, Prieto VG, Stewart AL, Mhashilkar AM, Chada S, Grimm EA. Negative association of melanoma differentiation-associated gene (mda-7) and inducible nitric oxide synthase (iNOS) in human melanoma: MDA-7 regulates iNOS expression in melanoma cells. Mol Cancer Ther 2(1):9-17, 2003. PMID: 12533668.
48. Simeone AM, Ekmekcioglu S, Broemeling LD, Grimm EA, Tari AM. A novel mechanism by which N-(4-hydroxyphenyl)retinamide inhibits breast cancer cell growth: the production of nitric oxide. Mol Cancer Ther 1(12):1009-17, 2002. PMID: 12481423.
49. Stewart AL, Mhashilkar AM, Yang XH, Ekmekcioglu S, Saito Y, Sieger K, Schrock R, Onishi E, Swanson X, Mumm JB, Zumstein L, Watson GJ, Snary D, Roth JA, Grimm EA, Ramesh R, Chada S. PI3 kinase blockade by Ad-PTEN inhibits invasion and induces apoptosis in RGP and metastatic melanoma cells. Mol Med 8(8):451-61, 2002. PMID: 12435856.
50. Caudell EG, Mumm JB, Poindexter N, Ekmekcioglu S, Mhashilkar AM, Yang XH, Retter MW, Hill P, Chada S, Grimm EA. The protein product of the tumor suppressor gene, melanoma differentiation-associated gene 7, exhibits immunostimulatory activity and is designated IL-24. J Immunol 168(12):6041-6, 2002. PMID: 12055212.
51. Ellerhorst JA, Prieto VG, Ekmekcioglu S, Broemeling L, Yekell S, Chada S, Grimm EA. Loss of MDA-7 expression with progression of melanoma. J Clin Oncol 20(4):1069-74, 2002. PMID: 11844832.
52. Ekmekcioglu S, Ellerhorst J, Mhashilkar AM, Sahin AA, Read CM, Prieto VG, Chada S, Grimm EA. Down-regulated melanoma differentiation associated gene (mda-7) expression in human melanomas. Int J Cancer 94(1):54-9, 2001. PMID: 11668478.
53. Ekmekcioglu S, Ellerhorst J, Smid CM, Prieto VG, Munsell M, Buzaid AC, Grimm EA. Inducible nitric oxide synthase and nitrotyrosine in human metastatic melanoma tumors correlate with poor survival. Clin Cancer Res 6(12):4768-75, 2000. PMID: 11156233.
54. Baba Y, Funakoshi T, Mori M, Emoto K, Masugi Y, Ekmekcioglu S, Amagai M, Tanese K. Expression of monoacylglycerol lipase as a marker of tumour invasion and progression in malignant melanoma. J Eur Acad Dermatol Venereol. e-Pub 2017. PMID: 28681540.

Invited Articles

1. Ekmekcioglu S, Tang CH, Grimm EA. NO news is not necessarily good news in cancer. Curr Cancer Drug Targets 5(2):103-15, 2005. PMID: 15810875.
2. Chada S, Sutton RB, Ekmekcioglu S, Ellerhorst J, Mumm JB, Leitner WW, Yang HY, Sahin AA, Hunt KK, Fuson KL, Poindexter N, Roth JA, Ramesh R, Grimm EA, Mhashilkar AM. MDA-7/IL-24 is a unique cytokine--tumor suppressor in the IL-10 family. Int Immunopharmacol 4(5):649-67, 2004. PMID: 15120650.

Abstracts

1. Ekmekcioglu S. Chronic Inflammatory Microenvironment Defines the Pro-Tumorigenic Functions of IFN-g. 3rd International Molecular Immunology & Immunogenetics Congress Antalya – TURKEY, 2016.
2. Ekmekcioglu S., Roszik J., Woodman SE., Grimm EA.. Novel Therapeutic Approaches by Targeting CD74 Expression in Melanoma. EACR-AACR-SIC 2015:Anticancer Drug Action and Drug Resistance, Florence, Italy, 2015. e-Pub 2015.
3. Tanese K, Funakoshi T, Yasuda F, Ohi Y, Fukuyama M, Arakawa H, Ekmekcioglu S, Saito M.. Squamous cell carcinoma showing marked attenuation of local lymphocytic infiltration along with the tumor invasion. 11th Meeting of the German-Japanese Society of Dermatology (GJSD), Heidelberg, Germany, 2014.
4. Dal F, Kim SH, Qin Y, Hashimoto Y, Ekmekcioglu S. Alterations in Mitochondrial Dynamics Regulate Melanoma Tumor Progression. Society for Free Radical Biology & Medicine Meeting, Seattle, WA, 2014.
5. Ekmekcioglu S, Myung SS, Tanese K, Bassett R, Milton DR, Prieto VG, Davies MA, Gershenwald J, Hoon D, Grimm EA. Association of CD74 Expression with Clinical Outcome in Stage III Melanoma. Society for Melanoma Research 2014 Meeting, Zurich, Switzerland, 2014.
6. Kim SH, Hashimoto Y, Ekmekcioglu S, Grimm EA.. Interaction between mPGES-1 and iNOS promotes human melanoma progression. AACR Annual Meeting 2014, San Diego, CA, 2014.
7. Ekmekcioglu S., Myung Shin-Sim M., Tanese T., Bassett R., Prieto VG., Dave S. Hoon DS., Morton ML., Grimm EA.. An Inflammatory Signature and Clinical Outcome in Stage III Melanoma: A Large-Scale Tissue Micro Array Study. Society for Melanoma Research - 2013 Congress, Philadelphia, PA, 2013.
8. Ekmekcioglu S., Tanese K., Qin Y., Grimm E. A. Targeting NO-driven Inflammation in Human Melanoma via IL-1s and CXCL-10. 2013 15th International Congress of Immunology, Milan-Italy, 2013.
9. Chen JQ, Creasy C, Torres Cabala CA, Ekmekcioglu S, Maiti SN, Roszik J, Haymaker C, Bernatchez C, Hwu P, Radvanyi L.. Identification of predictive biomarker signatures in melanoma tumors associated with response to tumor-infiltrating lymphocyte (TIL) therapy. Journal for ImmunoTherapy of Cancer 1(S1):P48, 2013.
10. Qin Y, Greene VR, Chattopadhyay C, Ekmekcioglu S, Liu C, Grimm EA.. Induction of hypoxia in 3D human melanoma spheroids leads to c-Met activation and resistance to Vemurafenib. Cancer Research 15(73):2936, 2013.
11. Ekmekcioglu S, Gabisi Jr AM, Wang Y, Fast W. Targeting Nitric Oxide Production via Dimethylarginases for Melanoma Therapy. Society for Melanoma Research 2012 Congress, Hollywood, CA, 2012.
12. Ekmekcioglu S, Tanese K, Qin Y, Grimm EA. Targeting NO-driven Inflammation in Human Melanoma: IL-1s and CXCL-10. Society for Melanoma Research 2012 Congress, Hollywood, CA, 2012.
13. Ekmekcioglu S, Tanese K, Qin Y, Grimm EA. NO-driven Inflammation in Human Melanoma via IL-1s and CXCL-10. Society for Free Radical Biology & Medicine Meeting, San Diego, CA, 2012.
14. Tanese K, Grimm EA, Ekmekcioglu S. Nitric Oxide Suppresses the Expression of CXCL10 and Leads to the Poor Outcome of Stage III Malignant Melanoma. EACR 22 - 22nd Biennial Congress of the European Association for Cancer Research, Barcelona, Spain, 2012.
15. Tanese K, Grimm EA, Ekmekcioglu S. CD74 expression on human melanoma serves as a marker of progression and a target for apoptotsis induction. 72nd SID Annual Meeting to be held at the Raleigh Convention Center, Raleigh, North Carolina, 2012.
16. Ekmekcioglu S, Qin Y, Deng W, Grimm EA. A large-scale synthetic lethal RNAi screening identifies unique sensitizing targets for anti-inflammatory CDDO-Me in metastatic melanoma. AACR Annual Meeting 2012, Chicago, Illinois, 2012.
17. Zhou H, Ekmekcioglu S, Marks JW, Asrani K, Phillips KK, Brown S, Cheng E, Weiss MB, Hittelman WN, Tran NL, Yagita H, Winkles JA, Rosenblum MG. (Fn14) Is a novel target in melanoma: Characterization of unique targeted therapeutics. AACR Annual Meeting 2012 Chicago, Illinois, 2012.
18. Ekmekcioglu S, Chattophadyay C, Akar U, Newman RA, Grimm EA.. Zyflamend Mediates Therapeutic Induction of Autophagy to Apoptosis in Melanoma Cells: iNOS and COX-2 Play a Role as Inflammatory Mediators. SFRR-E, Society for Free Radical Research-Europe, Istanbul, Turkey, 2011.
19. Zhou H, Marks JW, Ekmekcioglu S, Hittelman WN, Tran N, Yagita H, Winkles JA, Rosenblum MG. Development of single chain immunotoxins targeting the fibroblast growth factor-inducible 14 (Fn14) receptor on solid tumor cells. AACR 102nd Annual Meeting 2011, Orange County Convention Center in Orlando, Florida, 2011.
20. Tanese K, Ekmekcioglu S, Grimm EA. Inducible nitric oxide synthase suppresses the expression of CXCL10 and hence leads to the poor outcome of Stage III malignant melanoma. AACR 102nd Annual Meeting 2011, Orange County Convention Center in Orlando, Florida, 2011.
21. Tanese K, Grimm EA, Ekmekcioglu S. Tumor derived nitric oxide suppresses the expression of CXCL10 and leads to the poor outcome of Stage ΙΙΙ melanoma. 2011 SID Annual Meeting, JW Marriot, Phoenix AZ, 2011.
22. Garrido-Laguna I, Kurzrock R, Wheler J, Falchook GS, Piha-Paul S, Fu S, Naing A, Hinojosa C, Mistry R, Scamardo A, Culotta KS, Ekmekcioglu S, Wen S, Camacho L, Ivy P, Hong DS. Dual Inhibition of VEGF Pathway: Phase I Trial of Bevacizumab and Cediranib in Advanced Solid Tumors. ASCO Annual Meeting 2011, McCormick Place, Chicago, IL, 2011.
23. Ekmekcioglu S, Chattophadyay C, Akar U, Newman RA, Grimm EA.. Zyflamend Mediates Therapeutic Induction of Autophagy to Apoptosis in Melanoma Cells. 7th International Conference of the Society for Integrative Oncology,New York Academy of Medicine, NY, 2010.
24. Ekmekcioglu S, Tanese K, Grimm EA.. Inflammatory Pathway Arrays for Melanoma Molecular Profiling. Perspectives in Melanoma XIV, The Novotel Amsterdam City, The Netherlands, 2010.
25. Qin Y, Ekmekcioglu S, Poindexter NJ, Ellerhorst JA, Grimm EA.. Elevated Expression of IL-1 drives iNOS/NO Production and Inhibits IL-1Ra Synthesis Leading to Progression of Metastatic Melanoma. AACR 101st Annual Meeting 2010, Walter E. Washington Convention Center Washington, DC, 2010.

Book Chapters

1. Kim SH, Ogata D, Roszik J, Grimm EA, and Ekmekcioglu S. Arginine metabolism regulates nitric oxide production in melanoma tumor microenvironment to provide survival advantage to tumor cells. In: Therapeutic Application of Nitric Oxide in Cancer and Inflammatory Disorders. 1st. Elsevier: Cambridge, MA, 113-122, 2019.
2. Ekmekcioglu S and Grimm EA. Cytokines, Interferons and Hematopoietic Growth Factors. In: Cancer Medicine. 9th. Wiley & Sons Inc: New Jersey, 743-756, 2017.
3. Ekmekcioglu S., Kurzrock R., and Grimm EA.. Hematopoietic Growth Factors and Cytokines. In: The Molecular Basis of Cancer. 4th. Elseiver Inc: Philadelphia, 789-808, 2015.
4. Ekmekcioglu S, Kurzrock R, Grimm EA.. Hematopoietic Growth Factors and Cytokines. In: The Molecular Basis of Cancer. 3rd. Saunders Elsevier: Philadelphia, PA, 2012.
5. Ekmekcioglu S, Kurzrock R, Grimm, EA.. Cytokines and Growth Factors. In: Cancer Medicine. 8th. B.C.Decker Inc: Hamilton, Ontario, 686-709, 2010.
6. Ekmekcioglu S. Grimm EA.. Prognostic Significance of iNOS in Melanoma. In: Nitric Oxide and Cancer: Prognosis, Prevention and Therapy. Springer: New York, 293-308, 2010.
7. Poindexter N, Ramesh R, Ekmekcioglu S, Ellerhorst J, Kim K, Grimm EA.. Interleukin-24 Gene Therapy for Melanoma. In: Gene Based Therapies for Cancer. Springer: New York, NY, 181-202, 2010.
8. Ramesh R, Shanker M, Yokoyama T, Branch CD, Scott AW, Jin J, Zheng M, Bocangel D, Ekmekcioglu S, Poindexter N, Fuson K, Sutton BR, Grimm EA, Chada S.. To kill not to kill cancer cells: A perspective of MDA-7/IL-24. In: Recent Research Developments in Cancer. Transworld Research Network: Kerala, India, 2009.
9. Ekmekcioglu S, Kurzrock R, Grimm EA.. Hematopoietic Growth Factors and Cytokines. In: The Molecular Basis of Cancer. 3rd. Elsevier: Philadelphia, PA, 605-619, 2008.
10. Ekmekcioglu S, Grimm EA, Kurzrock R.. Cytokines and Growth Factors. In: Cancer Medicine. 7th. B.C. Decker Inc: Hamilton, Ontario, 744-769, 2006.
11. Ekmekcioglu S, Grimm, EA.. Cytokines: Biology and Application. In: Cancer Medicine. 6th. D.W. Kufe, R.E. Pollock, R.R. Weichselbaum, R.J. Bast, R. Gansler, J.F. Holland, and E. Frei III (eds), Holland-Frei Cancer Medicine e.6. B.C. Decker Inc: Hamilton, Ontario, 843-853, 2003.
12. Ekmekcioglu, S, Grimm, EA.. Nitric Oxide (NO) in Cancer: Potential Prognostic Factor?. In: Recent Research Developments in Cancer. Transworld Research Network: Kerala, India, 177-187, 2002.